talactoferrin alfa has been researched along with Lung Neoplasms in 9 studies
talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "TLF, in combination with C/P, demonstrated an apparent improvement in RR, PFS, and OS in patients with previously untreated stage IIIB/IV non-small cell lung cancer and appears to enhance activity without significant additional toxicity." | 2.76 | A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. ( Advani, SH; Bapna, A; Digumarti, R; Doval, DC; Julka, PK; Madhavan, J; Malik, R; Nag, S; Parikh, PM; Patil, S; Raman, G; Ranade, AA; Varadhachary, A; Wang, Y, 2011) |
| " Oral TLF or placebo was administered for a maximum of three 14-week cycles with dosing for 12 consecutive weeks followed by 2 weeks off." | 2.76 | Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. ( Advani, SH; Bapna, A; Digumarti, R; Ismail, PM; Madhavan, J; Malik, R; Nag, S; Parikh, PM; Patil, S; Sekhon, JS; Vaid, A; Varadhachary, A; Wang, Y; Zhu, J, 2011) |
| "Thirty-six patients with metastatic cancer who had progressed on, or were ineligible for, standard chemotherapy received single-agent oral talactoferrin." | 2.75 | Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors. ( Falchook, GS; Hayes, TG; Varadhachary, A, 2010) |
| "Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for approximately 85% of all cases." | 2.48 | What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? ( Reck, M, 2012) |
| "Talactoferrin alpha is an oral immunomodulatory agent currently in late-stage clinical trials that acts through dendritic cell recruitment and activation in the gut-associated lymphoid tissue." | 2.46 | The role of talactoferrin alpha in the treatment of non-small cell lung cancer. ( Giaccone, G; Kelly, RJ, 2010) |
| "Talactoferrin alfa (TLF) is a unique recombinant form of human lactoferrin." | 1.40 | Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. ( Bhattacharya, N; Blenman, KR; Engleman, E; Hwang, G; Lee, PP; Malik, R; Neal, JW; Pultar, P; Riess, JW; San-Pedro Salcedo, M; Wakelee, HA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Madan, RA | 1 |
| Tsang, KY | 1 |
| Bilusic, M | 1 |
| Vergati, M | 1 |
| Poole, DJ | 1 |
| Jochems, C | 1 |
| Tucker, JA | 1 |
| Schlom, J | 1 |
| Giaccone, G | 2 |
| Gulley, JL | 1 |
| Riess, JW | 1 |
| Bhattacharya, N | 1 |
| Blenman, KR | 1 |
| Neal, JW | 1 |
| Hwang, G | 1 |
| Pultar, P | 1 |
| San-Pedro Salcedo, M | 1 |
| Engleman, E | 1 |
| Lee, PP | 1 |
| Malik, R | 3 |
| Wakelee, HA | 1 |
| Hayes, TG | 1 |
| Falchook, GS | 1 |
| Varadhachary, A | 3 |
| West, HJ | 1 |
| Kelly, RJ | 1 |
| Digumarti, R | 2 |
| Wang, Y | 2 |
| Raman, G | 1 |
| Doval, DC | 1 |
| Advani, SH | 2 |
| Julka, PK | 1 |
| Parikh, PM | 2 |
| Patil, S | 2 |
| Nag, S | 2 |
| Madhavan, J | 2 |
| Bapna, A | 2 |
| Ranade, AA | 1 |
| Vaid, A | 1 |
| Sekhon, JS | 1 |
| Ismail, PM | 1 |
| Zhu, J | 1 |
| Reck, M | 1 |
| McBride, D | 1 |
3 reviews available for talactoferrin alfa and Lung Neoplasms
| Article | Year |
|---|---|
Novel targeted agents for lung cancer.
Topics: Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Heat-Shock Prot | 2009 |
The role of talactoferrin alpha in the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evalu | 2010 |
What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cancer V | 2012 |
3 trials available for talactoferrin alfa and Lung Neoplasms
| Article | Year |
|---|---|
Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal | 2010 |
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Sm | 2011 |
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2011 |
3 other studies available for talactoferrin alfa and Lung Neoplasms
| Article | Year |
|---|---|
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; CD4-Positive T-Lymphocytes; Clinical Trials, Phase III as Topic; Dis | 2013 |
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactoferrin; Lung Neoplasms; Male; Middle Aged | 2014 |
Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase | 2007 |